Cart
sales@molnova.com
Ninerafaxstat trihydrochloride
CAS No. 2311824-72-1
Ninerafaxstat trihydrochloride( Ninerafaxstat trihydrochloride(2254741-41-6 Free base) )
Catalog No. M28893 CAS No. 2311824-72-1
Ninerafaxstat trihydrochloride shifts cellular metabolism to glucose oxidation from fatty acid oxidation.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 178 | In Stock |
|
| 5MG | 160 | In Stock |
|
| 10MG | 240 | In Stock |
|
| 25MG | 408 | In Stock |
|
| 50MG | 550 | In Stock |
|
| 100MG | 784 | In Stock |
|
| 200MG | 1051 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNinerafaxstat trihydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionNinerafaxstat trihydrochloride shifts cellular metabolism to glucose oxidation from fatty acid oxidation.
-
DescriptionNinerafaxstat trihydrochloride shifts cellular metabolism to glucose oxidation from fatty acid oxidation. Ninerafaxstat trihydrochloride improves overall mitochondrial respiration and reduces fatty acid oxidation, thereby inhibiting the proliferation and growth of cancer cells.
-
In Vitro——
-
In Vivo——
-
SynonymsNinerafaxstat trihydrochloride(2254741-41-6 Free base)
-
PathwayOthers
-
TargetOther Targets
-
RecptorAMPAR|AMPA
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2311824-72-1
-
Formula Weight524.87
-
Molecular FormulaC22H32Cl3N3O5
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 41.67 mg/mL (79.39 mM)
-
SMILESCOC1=C(OC)C(OC)=C(CN2CCN(CC2)CCOC(C3=CN=CC=C3)=O)C=C1.Cl.Cl.Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.O'Neill MJ, Witkin JM. AMPA receptor potentiators: application for depression and Parkinson's disease. Curr Drug Targets. 2007 May;8(5):603-20. Review.
molnova catalog
related products
-
N-benzoyltyramine
The roots of Litsea hypophaea.
-
RMC-6291
RMC-6291 is an orally active, covalent inhibitor of KRAS G12C (ON) that forms a tri-complex within tumor cells between KRAS G12C (ON) and cyclophilin A (CypA), thereby preventing KRAS G12C (ON) from signaling via steric blockade of RAS effector binding and eliciting deep and durable suppression of RAS pathway activity in KRAS G12C tumor models .
-
Beta-Tocotrienol
Beta-Tocotrienol to serve as a new anticancer agent for treating human lung and brain cancers. It inhibits the growth of both A549 (GI50=1.38±0.334μM) and U87MG (GI50=2.53±0.604μM) cells at rather low concentrations.
